The crisis engulfing the UK’s life sciences sector was not inevitable; it is the direct and predictable result of years of government policy paralysis. A failure to make crucial decisions and reforms has allowed a world-leading industry to drift into a state of serious decline, an entirely avoidable tragedy.
The symptoms of this paralysis are now acute. The decision by MSD to cancel its £1 billion research facility was a clear consequence of the government’s inaction. This was followed by Eli Lilly suspending its own investment and Sanofi scaling back its UK operations, both companies responding to a policy vacuum that has persisted for too long.
The paralysis stems from a deep-seated conflict within government. The need to support a key industrial sector has been consistently overridden by the Treasury’s reluctance to increase spending on healthcare or reform the pricing and tax systems. This internal gridlock has left the industry with no confidence in the UK’s long-term strategy.
The UK’s foundational strengths in science offer a chance for recovery, but this requires breaking the policy paralysis with a jolt of radical action. The government must now make the decisive choices it has been avoiding for years. Failure to do so will confirm that this crisis was not just avoidable, but a deliberate outcome of political inertia.